Table 1. Baseline characteristics.
Characteristics | N = 288 |
Age at diagnosis, median in years (range) | 51 (27–85) |
Range, ages (years) | n (%) |
<35 years | 22 (6.2) |
35–39 | 27 (11.1) |
40–49 | 78 (27.1) |
50–59 | 91 (31.6) |
60–69 | 50 (17.4) |
≥70 | 20 (6.6) |
Menopausal status | n (%) |
Premenopausal | 174 (60.4) |
Postmenopausal | 114 (39.6) |
Tumor size | n (%) |
TX | 3 (1.0) |
T1 | 7 (2.4) |
T2 | 107 (37.1) |
T3 | 71 (24.6) |
T4 | 100 (34.7) |
Lymph nodes | n (%) |
N0 | 64 (22.2) |
N1 | 124 (43) |
N2 | 86 (29.8) |
N3 | 14 (4.8) |
TNM | n (%) |
IIA | 49 (17) |
IIB | 61 (21.2) |
IIIA | 72 (25) |
IIIB | 92 (32) |
IIIC | 14 (4.8) |
Histologic subtype | n (%) |
Ductal | 274 (95.1) |
Lobular | 6 (2.1) |
Other | 8 (2.8) |
Tumor grade | n (%) |
G1 | 21 (7.3) |
G2 | 131 (45.5) |
G3 | 116 (40.3) |
Unknown | 20 (6.9) |
Estrogen receptor status | n (%) |
Positive | 178 (61.8) |
Negative | 110 (38.2) |
Progesterone receptor status | n (%) |
Positive | 142 (49.3) |
Negative | 146 (50.7) |
HER 2 | n (%) |
Positive | 103 (35.7) |
Negative | 184 (64) |
Unknown | 1 (0.3) |
Biological subtype (IHC4) | n (%) |
Luminal A | 39 (13.5) |
Luminal B, HER 2- | 80 (27.8) |
Luminal B, HER 2+ | 57 (19.8) |
Her 2 enriched | 46 (16) |
Triple Negative | 62 (21.5) |
Neoadjuvant Chemotherapy regimen | n (%) |
Anthracycline-based only | 11 (3.8) |
Taxanes-based only | 29 (10.1) |
Anthracycline and taxane based | 248 (86.1) |
Pathological response | n (%) |
pCR | 89 (30.9) |
No pCR | 199 (69.1) |
Characteristics | N = 288 |
Age at diagnosis, median in years (range) | 51 (27–85) |
Range, ages (years) | n (%) |
<35 years | 22 (6.2) |
35–39 | 27 (11.1) |
40–49 | 78 (27.1) |
50–59 | 91 (31.6) |
60–69 | 50 (17.4) |
≥70 | 20 (6.6) |
Menopausal status | n (%) |
Premenopausal | 174 (60.4) |
Postmenopausal | 114 (39.6) |
Tumor size | n (%) |
TX | 3 (1.0) |
T1 | 7 (2.4) |
T2 | 107 (37.1) |
T3 | 71 (24.6) |
T4 | 100 (34.7) |
Lymph nodes | n (%) |
N0 | 64 (22.2) |
N1 | 124 (43) |
N2 | 86 (29.8) |
N3 | 14 (4.8) |
TNM | n (%) |
IIA | 49 (17) |
IIB | 61 (21.2) |
IIIA | 72 (25) |
IIIB | 92 (32) |
IIIC | 14 (4.8) |
Histologic subtype | n (%) |
Ductal | 274 (95.1) |
Lobular | 6 (2.1) |
Other | 8 (2.8) |
Tumor grade | n (%) |
G1 | 21 (7.3) |
G2 | 131 (45.5) |
G3 | 116 (40.3) |
Unknown | 20 (6.9) |
Estrogen receptor status | n (%) |
Positive | 178 (61.8) |
Negative | 110 (38.2) |
Progesterone receptor status | n (%) |
Positive | 142 (49.3) |
Negative | 146 (50.7) |
HER 2 | n (%) |
Positive | 103 (35.7) |
Negative | 184 (64) |
Unknown | 1 (0.3) |
Biological subtype (IHC4) | n (%) |
Luminal A | 39 (13.5) |
Luminal B, HER 2- | 80 (27.8) |
Luminal B, HER 2+ | 57 (19.8) |
Her 2 enriched | 46 (16) |
Triple Negative | 62 (21.5) |
Neoadjuvant Chemotherapy regimen | n (%) |
Anthracycline-based only | 11 (3.8) |
Taxanes-based only | 29 (10.1) |
Anthracycline and taxane based | 248 (86.1) |
Pathological response | n (%) |
pCR | 89 (30.9) |
No pCR | 199 (69.1) |
pCR: pathological complete response